205 related articles for article (PubMed ID: 29928880)
1. UBE2S enhances the ubiquitination of p53 and exerts oncogenic activities in hepatocellular carcinoma.
Pan YH; Yang M; Liu LP; Wu DC; Li MY; Su SG
Biochem Biophys Res Commun; 2018 Sep; 503(2):895-902. PubMed ID: 29928880
[TBL] [Abstract][Full Text] [Related]
2. UBE2T promotes hepatocellular carcinoma cell growth via ubiquitination of p53.
Liu LP; Yang M; Peng QZ; Li MY; Zhang YS; Guo YH; Chen Y; Bao SY
Biochem Biophys Res Commun; 2017 Nov; 493(1):20-27. PubMed ID: 28935368
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of ubiquitin-conjugating enzyme E2 S overexpression in hepatocellular carcinoma.
Ma Y; Li K; Li S; Liang B; Liu Q; Mo Z
Int J Biol Macromol; 2018 Nov; 119():225-231. PubMed ID: 30041036
[TBL] [Abstract][Full Text] [Related]
4. UBE2S interacting with TRIM28 in the nucleus accelerates cell cycle by ubiquitination of p27 to promote hepatocellular carcinoma development.
Zhang RY; Liu ZK; Wei D; Yong YL; Lin P; Li H; Liu M; Zheng NS; Liu K; Hu CX; Yang XZ; Chen ZN; Bian H
Signal Transduct Target Ther; 2021 Feb; 6(1):64. PubMed ID: 33589597
[TBL] [Abstract][Full Text] [Related]
5. UBE2S promotes malignant properties via VHL/HIF-1α and VHL/JAK2/STAT3 signaling pathways and decreases sensitivity to sorafenib in hepatocellular carcinoma.
Wu J; Xu X; Wu S; Shi W; Zhang G; Cao Y; Wang Z; Wu J; Jiang C
Cancer Med; 2023 Sep; 12(17):18078-18097. PubMed ID: 37563971
[TBL] [Abstract][Full Text] [Related]
6. UBE2S mediates tumor progression via SOX6/β-Catenin signaling in endometrial cancer.
Lin M; Lei T; Zheng J; Chen S; Du L; Xie H
Int J Biochem Cell Biol; 2019 Apr; 109():17-22. PubMed ID: 30690078
[TBL] [Abstract][Full Text] [Related]
7. FBXO22 promotes the development of hepatocellular carcinoma by regulating the ubiquitination and degradation of p21.
Zhang L; Chen J; Ning D; Liu Q; Wang C; Zhang Z; Chu L; Yu C; Liang HF; Zhang B; Chen X
J Exp Clin Cancer Res; 2019 Feb; 38(1):101. PubMed ID: 30808376
[TBL] [Abstract][Full Text] [Related]
8. UBE2S is associated with malignant characteristics of breast cancer cells.
Ayesha AK; Hyodo T; Asano E; Sato N; Mansour MA; Ito S; Hamaguchi M; Senga T
Tumour Biol; 2016 Jan; 37(1):763-72. PubMed ID: 26245992
[TBL] [Abstract][Full Text] [Related]
9. Gain of UBE2D1 facilitates hepatocellular carcinoma progression and is associated with DNA damage caused by continuous IL-6.
Zhou C; Bi F; Yuan J; Yang F; Sun S
J Exp Clin Cancer Res; 2018 Nov; 37(1):290. PubMed ID: 30482241
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of Protein Phosphatase 1γ (PP1γ) Is Associated with Enhanced Cell Proliferation and Poor Prognosis in Hepatocellular Carcinoma.
Li C; Wu M; Zong G; Wan C; Liu Q; Zhou H; Hua L; Chen Y; Chen X; Lu C
Dig Dis Sci; 2017 Jan; 62(1):133-142. PubMed ID: 27921263
[TBL] [Abstract][Full Text] [Related]
11. UBE2S promotes the proliferation and survival of human lung adenocarcinoma cells.
Liu Z; Xu L
BMB Rep; 2018 Dec; 51(12):642-647. PubMed ID: 30545437
[TBL] [Abstract][Full Text] [Related]
12. UBE2S exerts oncogenic activities in urinary bladder cancer by ubiquitinating TSC1.
Tang H; Fang T; Ji M; Wang JP; Song LL; Zhang QY; Wu JS
Biochem Biophys Res Commun; 2021 Nov; 578():7-14. PubMed ID: 34520980
[TBL] [Abstract][Full Text] [Related]
13. UBE2S associated with OSCC proliferation by promotion of P21 degradation via the ubiquitin-proteasome system.
Yoshimura S; Kasamatsu A; Nakashima D; Iyoda M; Kasama H; Saito T; Takahara T; Endo-Sakamoto Y; Shiiba M; Tanzawa H; Uzawa K
Biochem Biophys Res Commun; 2017 Apr; 485(4):820-825. PubMed ID: 28257844
[TBL] [Abstract][Full Text] [Related]
14. UBE2O promotes hepatocellular carcinoma cell proliferation and invasion by regulating the AMPKα2/mTOR pathway.
Shi Z; Liu R; Lu Q; Zeng Z; Liu Y; Zhao J; Liu X; Li L; Huang H; Yao Y; Huang D; Xu Q
Int J Med Sci; 2021; 18(16):3749-3758. PubMed ID: 34790050
[TBL] [Abstract][Full Text] [Related]
15. UBE2S promotes cell chemoresistance through PTEN-AKT signaling in hepatocellular carcinoma.
Gui L; Zhang S; Xu Y; Zhang H; Zhu Y; Kong L
Cell Death Discov; 2021 Nov; 7(1):357. PubMed ID: 34785642
[TBL] [Abstract][Full Text] [Related]
16. ASPM is a novel marker for vascular invasion, early recurrence, and poor prognosis of hepatocellular carcinoma.
Lin SY; Pan HW; Liu SH; Jeng YM; Hu FC; Peng SY; Lai PL; Hsu HC
Clin Cancer Res; 2008 Aug; 14(15):4814-20. PubMed ID: 18676753
[TBL] [Abstract][Full Text] [Related]
17. TRIM65 triggers β-catenin signaling via ubiquitylation of Axin1 to promote hepatocellular carcinoma.
Yang YF; Zhang MF; Tian QH; Zhang CZ
J Cell Sci; 2017 Sep; 130(18):3108-3115. PubMed ID: 28754688
[TBL] [Abstract][Full Text] [Related]
18. Pseudogene PDIA3P1 promotes cell proliferation, migration and invasion, and suppresses apoptosis in hepatocellular carcinoma by regulating the p53 pathway.
Kong Y; Zhang L; Huang Y; He T; Zhang L; Zhao X; Zhou X; Zhou D; Yan Y; Zhou J; Xie H; Zhou L; Zheng S; Wang W
Cancer Lett; 2017 Oct; 407():76-83. PubMed ID: 28823960
[TBL] [Abstract][Full Text] [Related]
19. PDZ binding kinase, regulated by FoxM1, enhances malignant phenotype via activation of β-Catenin signaling in hepatocellular carcinoma.
Yang YF; Pan YH; Cao Y; Fu J; Yang X; Zhang MF; Tian QH
Oncotarget; 2017 Jul; 8(29):47195-47205. PubMed ID: 28525379
[TBL] [Abstract][Full Text] [Related]
20. P53 immunohistochemical scoring: an independent prognostic marker for patients after hepatocellular carcinoma resection.
Qin LX; Tang ZY; Ma ZC; Wu ZQ; Zhou XD; Ye QH; Ji Y; Huang LW; Jia HL; Sun HC; Wang L
World J Gastroenterol; 2002 Jun; 8(3):459-63. PubMed ID: 12046070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
